Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors Publisher Pubmed



Ghahrisaremi N1 ; Akbari B1 ; Soltantoyeh T1 ; Hadjati J1 ; Ghassemi S2 ; Mirzaei HR1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

Source: Frontiers in Immunology Published:2021


Abstract

Chimeric antigen receptor (CAR) T cell therapy has shown unprecedented success in treating advanced hematological malignancies. Its effectiveness in solid tumors has been limited due to heterogeneous antigen expression, a suppressive tumor microenvironment, suboptimal trafficking to the tumor site and poor CAR T cell persistence. Several approaches have been developed to overcome these obstacles through various strategies including the genetic engineering of CAR T cells to blunt the signaling of immune inhibitory receptors as well as to modulate signaling of cytokine/chemokine molecules and their receptors. In this review we offer our perspective on how genetically modifying cytokine/chemokine molecules and their receptors can improve CAR T cell qualities such as functionality, persistence (e.g. resistance to pro-apoptotic signals) and infiltration into tumor sites. Understanding how such modifications can overcome barriers to CAR T cell effectiveness will undoubtedly enhance the potential of CAR T cells against solid tumors. © Copyright © 2021 Ghahri-Saremi, Akbari, Soltantoyeh, Hadjati, Ghassemi and Mirzaei.
Other Related Docs
9. Neurological Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy, Expert Review of Clinical Immunology (2023)
14. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
20. Crispr/Cas9 Revitalizes Adoptive T-Cell Therapy for Cancer Immunotherapy, Journal of Experimental and Clinical Cancer Research (2021)
21. Tumor Immunology, Clinical Immunology (2022)
23. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
24. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
28. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
29. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)
31. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
46. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)